What is Century Therapeutics, Inc.'s (IPSC) StockRank?

MoatMap's StockRank for Century Therapeutics, Inc. (IPSC) is 30/100, with a Sell signal. This is a composite score combining Quality (31), Value (30), and Momentum (59) factor ranks across MoatMap's 20,000+ stock universe.

Does Century Therapeutics, Inc. have an economic moat?

Century Therapeutics, Inc. (IPSC) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Century Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Century Therapeutics, Inc. (IPSC) is Sell, based on a StockRank of 30/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Century Therapeutics, Inc. in?

Century Therapeutics, Inc. (IPSC) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

IPSC

SELL

Century Therapeutics, Inc. · Healthcare · United States · $381M · Avg Vol: $4M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-42.7%

D/E

0.2x

Dividend %

—

COMPANY DESCRIPTION

Century Therapeutics, Inc. is a biotechnology company focused on developing allogeneic induced pluripotent stem cell (iPSC)-derived cell therapies for various cancers. Leveraging its proprietary iPSC platform, the company aims to create off-the-shelf, gene-edited cell therapies that can be administered to a broad patient population. This innovative approach positions Century as a key player in the emerging field of iPSC-based oncology treatments.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	5.2M	2.2M	6.6M	109.2M	175.9%	—
EPS	-0.74	-0.77	-0.77	-0.07	—	-1.11
Shares	180.4M	180.4M	180.4M	180.4M	0.0%	180.4M
Debt	49.4M	48.2M	53.8M	43.6M	-4.1%	48.0M
Equity	302.7M	184.8M	161.4M	158.9M	-19.3%	—
Op CF	14.1M	-88.3M	-110.1M	-103.9M	—	-94.5M
Inv CF	-13.1M	61.1M	47.5M	107.5M	—	—
Fin CF	27.2M	-9.7M	74.6M	0.2M	—	—

Loading 1Y...

PRICE (1Y)-5.8%

SMA 50SMA 200

$2.11

RSI (14)

34.4

52W High

$3.04

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

-5.2%40.3

ROE

-42.7%20.9

GP/Assets

-38.5%2.1

Op. Margin

0.0%41.3

FCF/Assets

-24.0%15.1

Piotroski

439.0

Int. Cover

—N/A

D/E Ratio

0.18x52.5

Current Ratio

10.25x86.9

Value

P/E (TTM)

—N/A

EV/EBITDA

-3.0x25.0

P/FCF

—N/A

P/B

1.5x72.1

P/S

—0.3

Div Yield

—N/A

Momentum

52W High %

69%53.3

RS 6M

-16%54.0

SMA 50/200

1.31x94.4

EPS Rev 4W

0.0%62.5

EPS Rev 12W

+13.7%88.9

EPS Improve

+59%59.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$381M

P/E (Forward)

-4.8x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IPSC are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
IPSC	Century Therapeutics, Inc.(you)	$381M	30	SELL
AVIR	Atea Pharmaceuticals, Inc.	$379M	30	SELL
CCCC	C4 Therapeutics, Inc.	$376M	33	SELL
PALI	Palisade Bio, Inc.	$339M	28	SELL
XFOR	X4 Pharmaceuticals, Inc.	$363M	32	SELL
SGMT	Sagimet Biosciences Inc.	$437M	28	SELL
PRTC.L	PureTech Health plc	$421M	27	SELL
ENTA	Enanta Pharmaceuticals, Inc.	$372M	24	SELL
OABI	OmniAb, Inc.	$294M	30	SELL
OVID	Ovid Therapeutics Inc.	$435M	33	SELL

Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%

Century Therapeutics, Inc. (IPSC) — Stock Score Summary

Century Therapeutics, Inc. (IPSC) has a MoatMap StockRank of 30/100 based on Quality (31/100), Value (30/100), and Momentum (59/100) factor scores. The current signal is SELL.

Key Financial Metrics

Price	$2.11
Market Cap	$381M
P/E (Forward)	-4.79
Price/Book	1.49
Return on Equity	-42.7%
Return on Invested Capital	-5.2%
Debt/Equity	0.18x
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-54M

Century Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Century Therapeutics, Inc.’s (IPSC) StockRank?: MoatMap’s StockRank for Century Therapeutics, Inc. (IPSC) is 30/100, with a Sell signal. It is a composite of Quality (31), Value (30), and Momentum (59) factor ranks across MoatMap’s 20,000+ stock universe.
Does Century Therapeutics, Inc. have an economic moat?: Century Therapeutics, Inc. (IPSC) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Century Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Century Therapeutics, Inc. (IPSC) is Sell, based on a StockRank of 30/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Century Therapeutics, Inc. in?: Century Therapeutics, Inc. (IPSC) operates in the Healthcare sector, specifically the Biotechnology industry (United States).